Ken Griffin Horizon Therapeutics Public LTD CO Call Options Transaction History

Citadel Advisors LLC

5 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2023 Nov 14, 2023	SELL	$98.98 - $115.74 $22.4 Million - $26.2 Million	-226,800 Reduced 28.4%	571,700 $66.1 Million
Q2 2023 Aug 14, 2023	BUY	$96.34 - $112.38 $74.8 Million - $87.2 Million	776,000 Added 3448.89%	798,500 $82.1 Million
Q1 2023 May 15, 2023	SELL	$107.32 - $113.5 $60.1 Million - $63.5 Million	-559,800 Reduced 96.14%	22,500 $2.46 Million
Q4 2022 Feb 14, 2023	BUY	$62.39 - $113.8 $25.6 Million - $46.7 Million	410,300 Added 238.55%	582,300 $66.3 Million
Q3 2022 Nov 14, 2022	BUY	$58.92 - $84.67 $5.26 Million - $7.55 Million	89,200 Added 107.73%	172,000 $10.6 Million

2.07M

20K

Ticker HZNP
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 230,384,000
Description
Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. The company operates in two segments, Orphan and Inflammation. Its portfolio comprises 12 medicines ...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.